Subcutaneous ustekinumab (DrugBank: Ustekinumab)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 56 | Behcet disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02648581 (ClinicalTrials.gov) | June 14, 2017 | 21/12/2015 | Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease | A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease | Behçet Disease | Drug: Subcutaneous Ustekinumab | Assistance Publique - Hôpitaux de Paris | NULL | Active, not recruiting | 18 Years | N/A | All | 16 | Phase 2 | France |